Previous 10 | Next 10 |
Preliminary data demonstrate that SENS-401 has a favorable safety profile when administered continuously for up to 11 weeks in adult patients undergoing cisplatin-based chemotherapy Recruitment is progressing well, with over a third of the required study population enrolled ...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the appointment of Bernd Schmidt...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Wedne...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce that its management team, includi...
Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, is pleased to announce its partic...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, is pleased to announce its participation, in-person...
Regulatory News: Sensorion (FR0012596468 – ALSEN) , a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, Sensorion announces the availability of its 1st H...
Sensorion to host a webconference dedicated to shareholders on September 25 th , 2023, in French, at 6am ET (12pm CET) Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel...
Development milestone achieved for SENS-501 (OTOF-GT) program with the submission of Clinical Trial Applications in the UK and in Europe GJB2-GT advancing towards IND-enabling activities after candidate selection Positive preliminary efficacy results of Proof-of-Concept Ph...
Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announced that it has submitted ...
News, Short Squeeze, Breakout and More Instantly...
RiverNorth Flexible Municipal Income Fund Inc. Company Name:
RFM Stock Symbol:
NYSE Market:
RiverNorth Flexible Municipal Income Fund Inc. Website:
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the appointment of Ms Laurene Danon ...
2024-06-24 06:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces that promising new data and analysis...